Immunotherapies versus small-molecule therapies of cancers with RAS oncogene mutations

Piotr Rieske

doi:10.5114/pja.2025.148075

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2025
vol. 12

Send email

Copy url:

abstract:

Review paper

Immunotherapies versus small-molecule therapies of cancers with RAS oncogene mutations

Piotr Rieske

^{1, 2}

Department of Research and Development, Personather, LTD/Personather Sp. z o.o., Konstantynow Lodzki, Poland
Department of Tumor Biology, Chair of Medical Biology, Medical University of Lodz, Lodz, Poland

Alergologia Polska – Polish Journal of Allergology 2025; 12, 2: 111–116

DOI: https://doi.org/10.5114/pja.2025.148075

Online publish date: 2025/03/04

View full text Get citation

PlumX metrics:

In recent years, it has become common for oncologists to compare the effects of small-molecule targeted therapies with immunotherapies. There are even no confrontational comparisons. The situation is similar for cancers exhibiting mutations of the RAS gene. However, it turns out that these cancers offer a unique opportunity to combine these two therapeutic interventions. Immunotherapy provides a possibility to overcome drug resistance to small-molecule compounds, but small-molecule therapy can sometimes facilitate the development of immunotherapies that overcome such drug resistance. The best-described example is the combination of covalent (irreversible) small-molecule therapy, against the RASG12C mutant, with immunotherapy relying on an antibody that recognizes the neoantigen, within which the covalent small-molecule compound (the blocker against which the drug resistance applies) is present.

keywords:

Immunotherapies versus small-molecule therapies of cancers with RAS oncogene mutations

Piotr Rieske 1, 2

RAS oncogene, CAR-T therapy (chimeric antigen receptors T cell), immunotherapy, small molecules, cancer

Piotr Rieske

^{1, 2}